hs235
Recombinant proteinexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 28, 2024 (NCT06714825)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Inhibin beta A chainANTAGONIST
INHBA antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07143448 | Phase 1 | Oct 31, 2025 | 35Pharma Inc |
| NCT07123779 | Phase 1 | Sep 30, 2025 | 35Pharma Inc |
| NCT06714825 | Phase 1 | Nov 28, 2024 | 35Pharma Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 35Pharma Inc | For profit | 3 | 3 | 1 | 2024 |
1 organizations
Page 1 / 1